Thanks, Alan. Before discussing overall market developments, I'd like to provide an update on the properties we previously disclosed, where tenants Parallel and Green Peak have not paid rent. As we noted then, and I think it's worth repeating here, we are, of course, first and foremost focused on maximizing the value of each of our properties and having tenants with strong teams that can manage their businesses successfully through the inevitable ups and downs of this industry. We have engaged local counsel and other advisers in these situations, commenced legal proceedings for damages and possession and are in discussions with applicable regulatory agencies. With our veteran team internally, in combination with our advisers across a spectrum of specialties, I am confident in our ability to successfully navigate these situations. In March, as many of you may know, Green Peak was placed into receivership. And in mid-March, we regained possession of the Summit building. In addition, we regained possession of 2 small retail locations in Michigan, previously leased to Green Peak, for which our total investment is less than $3 million. The receiver is paying rent on all other remaining properties leased to Green Peak, including the Harvest Park cultivation and processing facility and 4 other retail locations, and we are closely monitoring the situation and receivership process. We are currently in the process of discussing and touring the Summit property with interested cannabis operators. As noted on our prior call, we also filed actions against Parallel for possession and damages at our Pennsylvania property and our Texas property, which is in the early stages of development. We regained possession of the Texas property in March, where Parallel failed to pay rent for the first time in February. We are actively exploring all options for these properties, including speaking to a number of interested parties. As we noted previously, Parallel continues to be current on their obligations for the 2 other properties we leased to them in Florida. Late last month, Parallel announced that it is ending its Pennsylvania operations on September 15, including at our facility and at its medical cannabis dispensaries in the towns of and Erie. We are closely monitoring the situation and continue to be in active discussions with a number of parties. Market developments. While it is clear that the regulated cannabis industry has experienced in the past several months and continues to experience a set of challenging circumstances, I would like to note that the growth of the overall cannabis industry in the United States is expected to continue to be strong, with industry research group, New Frontier Data projecting a doubling of annual sales from 2023 to 2030 to over $70 billion, representing a double-digit compound annual growth rate. The regulated cannabis industry remains an exceptional case of industry size and growth potential. As we have noted for some time now, unit pricing for regulated cannabis products have been challenged in certain states at the wholesale level, reflective of what we believe to be a number of factors, including basic supply, demand dynamics, lack of meaningful enforcement in certain states on illicit nonlicensed cannabis sales by state and local enforcement authorities, taxation and general macroeconomic conditions. Reflecting that continued price compression in combination with the continued inflation on input and labor costs, we note that consensus analyst expectations for 2023 and 2024 sales and EBITDA growth have fallen significantly for publicly traded U.S. operators nearly across the board. That said, this price compression dynamic is certainly not uniform across states, and we are cautiously optimistic that certain states, like California and Michigan, may be showing signs of price stability after months of declines. While new adult-use states, like Missouri and Maryland, are seeing very healthy wholesale price dynamics. According to cannabis benchmarks, there has been stabilization in average wholesale pricing nationwide after significant declines last year, with recent nationwide wholesale pricing even showing a modest uptick in July versus pricing in December of last year. Capital availability. Another continuing theme from our prior calls is the tightening of financial conditions and the impact it continues to have on capital availability for the cannabis industry. As with other industries, the cost of capital and capital availability have fundamentally changed for cannabis operators over the course of the past year plus. As we noted previously, capital raising across the cannabis industry continues to be very subdued, with Viridian Capital Advisors reporting that U.S. operator capital raises were down more than 3 quarters in the first half of 2023 versus the prior-year period. And of those raises, over 85% was in the form of debt. The continued focus on debt in combination with ongoing pressure on equity valuations, with cannabis equities seeing further significant drawdowns in pricing over the first half of 2023, have driven a handful of publicly traded MSOs to have a debt-to-market cap ratio in excess of 5x. As we noted from our prior call, we believe the present macroeconomic challenges of unit pricing compression and cost inflation, in combination with depressed valuations and capital availability, have translated into the larger MSOs focusing more on efficiency of existing operations and generating positive free cash flow versus growth through M&A. That certainly appeared to continue to be the case through the first half of this year, where we saw just over $1 billion in U.S. M&A transaction versus $2 billion in the first half of 2022 and $6 billion in the first half of 2021. State programs. Shifting to state-specific programs, as noted in prior calls, we continue to see momentum for both adult-use and medical-use adoption and rollout. Missouri officially launched its adult-use program in February, with regulated cannabis sales in March totaling over $126 million alone. Maryland's adult-use cannabis program saw first legal sales on July 1, including over $10 million in sales in the first weekend alone. And in April, Delaware became the 22nd state to legalize adult-use cannabis with the licensing process they are expected to commence in 2024. In Minnesota, a bill legalizing adult-use cannabis was passed by both chambers, with the launch of the market projected in 2025. In March, Kentucky lawmakers overwhelmingly passed legislation to establish a medical cannabis program which is also expected to launch in 2025. In Florida, a legalization campaign has already collected in excess of 1 million signatures to put on a recreational use referendum on the ballot next year, with Florida having the largest medical cannabis program already in the country, including more than 830,000 enrolled patients. We're also tracking other potential referendums or legislation regarding establishing regulated cannabis programs, including for adult use in Ohio, in South Dakota and medical cannabis programs in Nebraska, Idaho and Wyoming. Federal legislation. On the federal legislation front, as you know, versions of the SAFE Act have been introduced numerous times over the last several years in both the House and Senate. Believe it or not, we are at the tenth anniversary for when the first version of the SAFE Act bill was introduced in 4 years after it first passed the house with more than 100 Republican votes. While Senate Majority Leader, Chuck Schumer's recent comments placed a priority on cannabis banking legislation, it remains highly uncertain whether such a bill could make it into the National Defense Authorization Act, one of the few bills passed each year on a bipartisan basis and one which has been targeted repeatedly as a vehicle to pass SAFE. As in calls past, we also want to note some of the recent legislative movement and commentary by federal officials and commercial organizations, which we believe show the continued momentum forward for change. In June, the House Armed Services Committee approved a version of the NDAA with provisions to create a medical marijuana pilot program to examine the health impacts of Marijuana used by veterans and service members who are DoD veteran of fair beneficiaries that are diagnosed with PTSD, depression or anxiety or have been prescribed pain management. Also in June, the Senate Appropriations Committee approved a spending bill that includes a provision allowing VA physicians to recommend medical cannabis as a potential treatment option for its veteran patients. Finally, also in June, the President of one of the largest labor unions in the country wrote to the Biden administration, urging comprehensive cannabis reform, including full descheduling of cannabis from the Controlled Substance Act and provisions to protect state-based industries from monopolization. I'd like to now turn the call over to Ben to discuss our investment and portfolio activity in the second quarter. Ben?